591 results on '"Ennishi, Daisuke"'
Search Results
2. Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects
3. Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma
4. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
5. Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report
6. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
7. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy
8. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis
9. Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma
10. Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation
11. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
12. Biological and clinical significance of epigenetic alterations in B-cell lymphomas
13. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
14. Chronic active Epstein–Barr virus infection presenting as refractory chronic sinusitis
15. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group
16. Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection
17. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma
18. Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
19. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
20. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
21. Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel
22. Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease
23. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
24. Combination of reduced post‐transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft‐versus‐host disease in human leukocyte antigen‐haploidentical peripheral blood stem‐cell transplantation
25. Recent updates on treatment options for primary follicular lymphoma of the gastrointestinal tract.
26. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial
27. Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel
28. Clinical significance of gynecological examinations in long-term follow-ups
29. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
30. Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient
31. Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series
32. Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
33. Author Correction: 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy
34. Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A > T: a case report
35. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
36. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy
37. Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab
38. Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma
39. Evaluating the efficiency and safety of large‐volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study
40. Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
41. 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy
42. Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch
43. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact
44. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
45. Genomic Profiling of a Case of Glioneuronal Tumor with Neuropil-like Islands
46. Long non‐coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B‐cell lymphoma
47. Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide
48. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
49. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
50. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.